Martín Cullell-Young

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Santiago Ponce Aix, Tudor–Eliade Ciuleanu, Alejandro Navarro et al. · The Lancet Respiratory Medicine · 2022 · 120 citations · Full text

Medicine, Oncology, Pharmacology +11

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors

María Elena Elez, Josep Tabernero, David Geary et al. · Clinical Cancer Research · 2014 · 89 citations

Pharmacy, Oncology, Pharmacology +16

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study

Emiliano Calvo, Víctor Moreno, Michael Flynn et al. · Annals of Oncology · 2017 · 85 citations · Full text

Medicine, Oncology, Pharmacology +12

Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma

V. Ribrag, Dolores Caballero, Christophe Fermé et al. · Haematologica · 2012 · 60 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study

Suzette Delaloge, R. Wolp-Diniz, Tomasz Byrski et al. · Annals of Oncology · 2014 · 48 citations · Full text

Medicine, Genetics, Oncology +14